Pomegra
Warsaw biotech Science4Beauty secures €1.6M in seed funding from 4growth VC and Hard2beat to scale its recombinant conotoxin platform and push into international aesthetics markets.
- Science4Beauty raised €1.6M (roughly 7 million PLN) in a seed round led by 4growth VC, with co-investor Hard2beat and a group of business angels.
- The company's flagship ingredient mimics sea snail venom to relax facial muscles without needles, clinically reducing wrinkle depth by up to 48%.
- Proceeds target international sales expansion and new bioactive molecules for dermatology and aesthetic medicine.
Lead
Science4Beauty, a Warsaw-based cosmeceutical biotech, closed a €1.6M seed round in September 2025, with 4growth VC as lead investor, Hard2beat as co-investor, and several business angels rounding out the cap table. Valuation was not disclosed. The company, founded in 2020 by Magdalena Janczewska, Dr. Anna Mazurkiewicz-Pisarek, Alina Mazurkiewicz, and Agata Stefanek, operates its own certified genetic engineering laboratory in Warsaw and holds patent applications across ten jurisdictions.
What Does Science4Beauty Actually Make?
The company's core output is a recombinant conotoxin - a bioactive peptide engineered to replicate the muscle-relaxing mechanism of toxins found in cone snail venom. In practical terms: it inhibits neuromuscular signal transmission at the skin's surface, smoothing wrinkles without injection. Their primary commercial line, Miorelaxant Magic™, achieved a 48% reduction in wrinkle depth in clinical trials and extended the visible effects of botulinum toxin treatments by approximately 60 days. The customer base spans aesthetic medicine clinics and direct-to-consumer channels through the company's online store.
This is not a conventional skincare play. Science4Beauty operates more like a specialty biotech - the recombinant production process replaces animal-derived or purely synthetic starting materials with proteins expressed in controlled biological systems. That positions the ingredient supply chain as more traceable and scalable than traditional extraction methods, a differentiating argument increasingly relevant to European cosmetics brands navigating tighter sustainability disclosures.
Why Is This Funding Round Significant for CEE Biotech?
The Central and Eastern European deep-tech funding environment has remained thin at the seed stage, particularly for life sciences. A €1.6M round is modest by Western European standards but meaningful within the Polish startup ecosystem, where biotech deals of this kind remain uncommon. 4growth VC has built a portfolio oriented toward Polish technology companies with cross-border ambitions, and its participation here signals a bet that cosmeceutical biotechs can generate commercial returns before reaching the capital intensity typical of pharmaceutical development.
The involvement of Hard2beat, a sports nutrition-adjacent investor, reflects an expanding thesis in that corner of the market: bioactive peptides that began in athletic recovery and dermatology are converging, and the same recombinant production infrastructure can serve both verticals. For Science4Beauty, the co-investor base gives it commercial networks beyond traditional pharma distribution channels.
Pipeline and What Comes After Wrinkles
Science4Beauty's disclosed pipeline extends well past wrinkle reduction. The company is developing bioactive molecules targeting hyperhidrosis (excessive sweating), rosacea, and delivery formats including microneedle patches - the last of which would allow transdermal active delivery without the regulatory and professional-setting constraints that come with injectable aesthetics.
Each of those applications runs on the same platform logic: produce a recombinant protein, validate its mechanism, formulate it for topical or patch delivery. The capital efficiency of that model relative to small-molecule drug development is a genuine structural advantage, though regulatory pathways for cosmeceuticals vary substantially across the EU, US, and Asian markets the company is targeting.
The patent portfolio covering ten jurisdictions is the clearest evidence of international ambition. Poland alone is not the addressable market here. The question is whether €1.6M is enough runway to reach the commercial milestones in Germany, France, or the UK that would justify a Series A from an investor outside Central Europe.
What Does the Competitive Field Look Like?
Sustainable cosmetic ingredients derived from biotech processes have attracted growing investment globally, with several well-funded competitors pursuing fermentation-derived actives and synthetic biology routes to high-performance molecules. Science4Beauty's differentiation rests on the specificity of its conotoxin mechanism - it is not a generic peptide supplier but a company with a defined biological target and clinical proof of effect. That narrowness is both a protection and a constraint: the path to broader ingredient licensing requires validating additional molecules faster than competitors can replicate the approach.
Outlook
Science4Beauty enters the next phase with a clinically validated lead product, a protected platform, and enough capital to pursue initial international sales without immediately diluting further. The seed round answers the question of whether the technology merits external confidence - it does, at least at this check size. The harder test is converting clinical data into B2B ingredient licensing agreements or white-label supply deals with European cosmetics manufacturers, where procurement cycles run long and reformulation decisions move slowly. A follow-on round, when it comes, will be defined less by the science and more by those commercial conversion numbers.
